Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RY_SW01 Cell Injection in Systemic Sclerosis
NCT06058091Phase 2Recruiting
- Sponsor
- Jiangsu Renocell Biotech
- Start
- Sep 2023
- Primary completion
- Dec 2025
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
A Phase 2 trial of 89zr-oxine-ry_sw01 in systemic sclerosis (SSc), sponsored by Jiangsu Renocell Biotech. Started Sep 2023; status: recruiting.
02
Drugs
89zr-oxine-ry_sw01
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT06058091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06058091.